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The introduction and expression of exogenous genetic 
material in cultured cells has provided a powerful tool 
for studying gene function and regulation. Immortal­
ized cell lines have been useful for establishing gene 
transfer methodologies that are generally inefficient. 
For investigators of epidermal and mucosal biology, 
wishing to make use of the tissue architecture pro­
duced by primary keratinocytes in vitro, the limited life 
A variety of gene transfer procedures have been devel­oped in recent years, some of which have already been used with keratinocytes. In general, genes are deliv­ered into target cells using chemical, physical, or bio­logic methods (Table I). Chemical approaches rely 
on the ability of DNA-containing particles to adhere to the surface 
of cells and to penetrate the cell membrane by endocytosis. Physical 
methods employ different means to create disruptions in the cell 
membrane to allow the entrance of genetic material into the cyto­
plasm. Alternatively, physical methods that disrupt membranes, 
such as microinjection, allow insertion of DNA directly into the cell 
nucleus. Biologic gene transfer techniques utilize viral vectors that 
adhere to specific cellular surface receptors and subsequently be­
come internalized. These approaches have been used to genetically 
alter keratinocytes in vitro and in vivo. 
Keratinocytes have several characteristics that make them well 
suited as target cells for gene transfer. In vitro culture conditions for 
the growth and proliferation ofkeratinocytes have been well estab­
lished [1] and have produced an intact tissue suitable for grafting [2]. 
The long-term success of cultured epithelial autografts in treating 
burn patients suggests that epidermal stem cells are present in cul­
ture [3]. A variety of keratinocyte model systems are available for 
testing the expression of genes during tissue maturation [4]. Kerati­
nocytes in these culture systems are capable of terminal differentia­
tion and of mimicking many of the biochemical and genetic proper­
ties of intact epidermis. Finally, if the transferred gene encodes a 
secreted protein, cultured keratinocytes have been shown to secrete 
both in vitro and after grafting [5]. 
GENE TRANSFER TECHNIQUES 
Chemical Techniques 
DNA-Mediated Transfection: A simple procedure that has been used 
to introduce a gene carried by a plasmid vector into cultured kerati­
nocytes is the incubation of cells with divalent cations such as cal­
cium [6] or strontium. The use of strontium was developed for 
mouse keratinocytes, which undergo terminal differentiation in the 
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span of these cells presents a host of unique problems. 
Primary cells require the use of gene transfer methods 
that are highly efficient and will not significantly alter 
the cell's normal differentiation pathway. The purpose 
of this review is to evaluate gene transfer technology as 
it applies to keratinocytes. Key words: epithelia/transfec­
tion/transduction.] Invest DermatoI10J:70S-7SS, 1994 
presence of high calcium but are insensitive to strontium [7]. Using 
DNA-mediated transfection, as many as 50% of the cells can take up 
DNA but generally only 1-10% will express the transfected gene 
[8]. Although the mechanism is not clearly understood, it is believed 
that transfected DNA enters the cytoplasm where it is often de­
stroyed by lysosomal enzymes before it can reach the nucleus. 
Agents such as chloroquine are helpful in stabilizing lysosomes and 
are often added for this purpose [9]. 
In the cases where the cloned DNA does enter the nucleus it 
usually persists and is expressed for several days but is eventually 
lost, this phenomenon is referred to as transient expression. In a 
small suhpopulation of the tr�sfected cells. (between 1 X 10-3 and 
1 X 10-6 ) the DNA becomes mcorporated mto the genome perma­
nently altering the cell resulting in stable expression. The integra­
tion event that causes stable expression of the newly introduced 
DNA is often accompanied by variability in copy number, deletions, 
and rearrangements. Co-transfection with a dominant drug resist­
ance gene, such as the gene encoding for neomycin B resistance 
(neor) [10] or hygromycin resistance [11], allows recovery of the 
rare, stably transformed cells. This system has been exploited in 
keratinocyte lines [12,13] as well as in primary keratinocytes 
[14,15]' 
Calcium-mediated DNA transfer has been compared to DEAE 
dextran- and polybrene-mediated transfection as far as effectiveness 
in introducing DNA into keratinocytes [16]. In the study of Jiang el 
al complexing the DNA with polybrene or lipids resulted in higher 
levels of transient gene expression than using calcium mediated 
gene transfer. However, irrespective of the gene transfer method, 
expression usually diminishes within several days. For this reason, 
these methods have seldom been successful for stable expression of 
exogenous DNA introduced into keratinocytes [17]. 
Lipofection: The use of artificial phospholipid vesicles or liposomes 
to deliver DNA has been extensively used with a variety of cell types 
[18]. Encapsulation within a lipid vesicle protects the DNA from 
hydrolysis and allows transport across the plasma membrane. Large 
U¢lamellar vesicles ranging from 0.2 to 4.0 J.lm can encapsulate up 
, to 40% of an aqueous buffer containing large macromolecules and 
subsequently deliver them to cells in a biologically active form [19]. 
The composition of liposome membranes can also be designed to 
target subpopulations of cells depending on surface receptors [20]. 
Lipofection is an efficient system of DNA delivery to primary kera­
tinocytes [16]. 
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Table I. Gene Transfer Technologies 
Chemical DNA-mediated transfection 
Lipofection 
Physical Microinjection 
Electroporation 
Micro-projectiles 
Biologic Retrovirus 
Adeno associated virus 
Adenovirus 
Human papillomavirus 
Epstein-Barr virus 
Physical Techniques 
Microinjection: Microinjection depends on the physical introduc­
tion of genetic material to the nucleus of each cell by use of a fine 
glass needle. It is the only technique that introduces the DNA 
directly into the cell nucleus. Although this is a laborious process 
because each cell has to be individually manipulated, it does permit 
one to examine expression with the certainty that known numbers 
of copies of the introduced gene are present in the target cell nu­
cleus. For example, microinjection of mucosal and epidermal kera­
tinocytes with gene constructs containing a promoter from human 
�pillomavirus showed that the promoter was indeed tissue specific 
121]. 
Eiectroporation: In recent years electroporation has become a 
method of choice for many cell types that cannot be passaged or that 
are grown in suspension [22]. This method for gene transfer uses a 
short high-voltage electric field to induce reversible micropores in 
the plasma membrane thereby allowing uptake of DNA from the 
medium [23]. Electroporation has been used to transfect murine 
keratinocytes [24], human epidermal keratinocytes [25,26)' and 
human cervical keratinocytes [27] . Defining optimal conditions for 
this technique is not trivial as consistent results have not been found 
by all investigators [16]. 
Biologic Expression Vectors The limitations in gene transfer 
using plasmid DNA are largely overcome with the use of eukaryotic 
viral vectors. In the last decade remarkable progress has been made 
in terms of developing retroviral vectors that are useful for effi­
ciently introducing genes into mammalian cells. Likewise, vectors 
that have been constructed based on four DNA viruses appear 
promising for use with cultured mammalian cells: adena-associated 
virus (AA V), adenovirus (Ad), human papillomavirus, (HPV), and 
Epstein-Barr virus (EBV). 
Eukaryotic plasmid vectors are constructed based on elements 
from varied cellular and viral sources. They can be categorized as 
episomal (freely replicating) or integrating (nonreplicating). They 
also vary in terms of host range and size of insert that can be accom­
modated (Table ll). 
Rttrovirus: Replication-defective retroviral vectors have been en­
gineered to produce a virus that cannot replicate, but can infect, if 
encapsidated by viral proteins in specifically designed packaging 
cells. This is achieved by the replacement of most or all of the 
coding region(s) of a retrovirus with the gene(s) to be transferred. 
Detailed protocols for generating infectious retrovectors beginning 
with the recombinant DNA have been published elsewhere [28]. 
The amount of DNA that can be inserted in retroviral vectors 
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varies but, generally, up to 10 kb of DNA can be accommodated 
[29]. Upon infection, viral RNA is reverse transcribed to DNA and, 
in dividing cells, is integrated as a single copy of proviral DNA [30]. 
Several variables must be considered in using retroviral vectors to 
transduce keratinocytes. A key factor in achieving efficient transfer 
is viral titer. For primary keratinocytes in culture, viral titers greater 
than 5 X 106 colony forming unit (CFU)/m1 result in transduction 
of all clonogenic cells whereas titers in the range of 105 transduce 
approximately 5% of the clonogenic cells [31]. Transduced kerati­
nocytes harboring a single copy of retrovector DNA can undergo up 
to 30 cell divisions before senescence. The number of cell divisions 
suggests that stem cells have been transduced. The significance of 
this will be discussed later. 
Improvements in vector design and in packaging cell lines [32] 
have led to vectors that yield high titers (107/colony-forming 
units/ml). However, it is also important to keep in mind that inser­
tion of the sequences of interest into the vector may affect viral 
titers. For example, the presence of a strong polyadenylation signal 
in the gene being inserted is likely to cause premature termination of 
the RNA in the packaging cell line and thus reduce viral titers of the 
full-length viral clones [33]. 
Primary cells have been successfully infected with retroviral vec­
tors provided the cells are replicating [34]. Until recently, it was 
assumed that retroviral integration depended on DNA synthesis. 
Current studies, however, suggest that integration depends on mi­
tosis rather than replication [35]. Whatever the mechanism, opti­
mal transduction rates will be obtained if a sizeable fraction of the 
population is dividing. 
Retroviral vectors have been successfully used for the transduc­
tion of keratinocytes, which when grown into a multilayered epi­
thelial sheet can be assayed for secretion of the transduced gene and 
subsequently used for grafting. Morgan et al [36] first showed that 
primary keratinocytes secreted human growth hormone when 
transduced with a retrovirus harboring that gene. If transfected into 
an immortal keratinocyte line this protein could be seen in the 
bloodstream of grafted mice [37]. 
Gerrard et al [38] have also reported successful transduction of 
primary keratinocytes. The construct utilized included the human 
factor IX gene under the control of the murine leukemia virus long 
terminal repeat with the neo' gene under the control of an SV 40 
promoter. The transduced keratinocytes were capable of synthesiz­
ing and secreting biologically active factor IX not only in culture 
but also into the bloodstream of grafted mice. Retroviral vectors are 
currently being used to transfer and express genes for a variety of 
uses including for the genetic modification of human somatic cells 
in order to correct genetic disease [39]. 
Adena Associated Virus (AAV): AA V is an animal DNA virus that 
belongs to the parvovirus family [40]. When AA V is coinfected 
with either adenovirus or herpes simplex virus it undergoes a pro­
ductive infection. In the absence of helper virus, AA V establishes a 
latent infection in which the viral genome integrates into the host 
genome [41]. Integration is not well understood and seems to occur 
only at one site in human cells (chromosome 19 qI3-qter) [42]. 
Latent infection can proceed to a normal productive infection if the 
cell is subsequently infected with helper virus. 
The use of AA Vas a viral transduction vector has been established 
for almost ten years [43]. The host range for AA V seems exception­
ally broad because every mammalian cel11ine thus far evaluated can 
be productively infected with AA V [44]. There is no pathology 
Table II. Comparison of Virus-Derived Vectors 
RV AAV 
Integration Yes Yes 
Host range Dividing cells All cells tested 
Maximum kb load 10 5.2 
Safety data Yes Some 
Ad 
No 
Non-dividing cells 
7.5 
Yes 
HPV 
No 
Epithelial cells 
? 
No 
EBV 
No 
Many human cells 
35 
No 
72S FENJVES 
associated with AA V and about 85% of normal adults are positive 
for serum antibodies to AAV capsid proteins [44]. 
Transduction frequencies of AA V vectors are between 0.5% and 
5%. There are limits to how much DNA can be packaged by AA V. 
Large inserts lower the infection rate, and although up to 5.2 kb can 
be accommodated, packaging this size is very inefficient. The 
promiscuity of this vector, coupled to its relatively high transduc� 
tion rate in human cells make AA V a potentially exciting candidate 
vector for introducing genes into cultured keratinocytes. 
Adenovirus (Ad): Ad vectors have a natural tropism for respiratory 
and oral epithelial cells [45] although they exhibit a broad host 
range specificity. During its lytic cycle the virus is taken up by cells, 
migrates to the nucleus, and does not integrate into the host chro­
mosome. In contrast, cells transformed with Ad have viral se­
quenc�s stably integrated into the cellular genome and no detectable 
free VIrUS present. 
Replication-defective adenoViruses have been developed as vec­
tors for therapeutic genes. Ad vectors are currently being used and 
have been engineered to introduce the human gene for the cystic 
fibrosis transmembrane conductance regulator [46] as well as for 
alpha-l-antitrypsin into human airway epithelium [47]. In contrast 
to retroviruses, adenoviruses infect non-dividing cells, a great ad­
vantage in targeting quiescent keratinocyte stem cells. By the same 
token, however, these vectors are likely to infect non-replicating, 
terminally differentiated cells, limiting expression to the transit 
times of these cells. In fact transient expression has been one of the 
main drawbacks to the Ad vector system. 
An important safety consideration that cannot be ignored in ref­
erence to vectors based on adenoviral sequences is that existing 
replication-defective adenoviral vectors may be rartially replica­
tion-competent. The responses that this low leve replication may 
elicit has not been determined [48,49]. 
Human Papillomaviruses (HPV): HPV are epitheliotropic and are 
distinguished by the fact that, in benign papillomatous lesions, mul­
tiple copies of viral DNA replicate as stable episomes. It is thought 
that basal cells maintain a low level stable replication ofHPV, and a 
high copy number in more differentiated superficial cells [50]. 
Genes transferred with a bovine papilloma virus-based vector, 
which is the most commonly used model for the study of papillo­
matous DNA replication, generally remain episomal, thus avoiding 
insertional mutagenesis and providing a multicopy pool of vector 
genomes for expression [51]. 
HPV type 1 derived from plantar warts has been used to infect 
human keratinocytes [52] as has HPV type 11, a genital-derived 
HPV [53]. HPV type 11 DNA has also been used to transfect cul­
tured human keratinocytes using calcium phosphate precipitation 
[14] . The fact that long-term episomal replication of HPV DNA 
was achieved by Mungal et af indicates that although they have yet 
to be developed, HPV -based vectors may prove to be extremely 
useful for targeting human keratinocytes. 
Epstein-Barr Virus (EBV): EBV, a member of the herpesvirus fam­
ily, normally infects B cells and certain nasopharyngeal cells. EB 
virions contain a linear DNA molecule of 172 kb that presumably 
circularizes via its terminal repeats and is thus maintained as an 
episome in the cell's nucleus [54]. DNA-mediated transfection of 
portions of this virus have been successful in establishing stably 
maintained plasmids in many cell lines [55]. 
EBV-based circular constructs have been used by Jensen et af to 
introduce the sulfatase gene into keratinocytes cultured from pa­
tients with X-linked ichthyosis. However, it has not yet been deter­
mined whether there is long-term expression resulting from this 
vector [15]. Recently, an EBV based vector was shown to have high 
transfection efficiency and to be maintained stably for at least six 
months in a human embryonic kidney cell line [56]. A potential 
unique advantage of vectors derived from EBV is their large capac­
ity. Inserts of up to 35 kb in length have been introduced with this 
vector [55]. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Dominant Selectable Genes As has been mentioned, there are a 
variety of dominant selectable genes that have been transferred ei­
ther as cotransfectant DNA or as an element within the viral vectors 
(for recent review [57]). These include resistance to various agents 
such as G418, hygromycin, methotrexate, puromycin, mycophen­
olic acid, xanthine, aminopterine, and histidinol (Table m). The 
aminoglycoside phosphotransferase gene (usually referred to as 
neor) confers resistance to G418, a neomycin analogue, and has been 
useful in keratinocytes. 
Selection of keratinocytes is not a simple matter and requires that 
various provisions be kept in mind. First, selection should begin 
after the transduced cells have completed at least two cycles of 
replication to allow time for integration and expression of the newly 
introduced gene. In our experience it is also advisable to begin 
G418-selection before individual colonies contain more than 5 -10 
cells. If the colonies become large, G418-resistant cells linked by 
desmosomaljunctions to neighboring G418-sensitive cells may be­
come dislodged when the sensitive cells become necrotic and are 
shed into the medium. By keeping colony size to a minimum, loss of 
neor cells by this mechanism seems to be reduced. 
Reporter Genes There are a number of reporter genes whose 
products can be detected histochemically or biochemically and have 
been very useful in monitoring expression against a low or zero 
background. One such reporter gene used in keratinocyte studies is 
the Escherichia coli lacZ gene that encodes for p-galactosidase (p-gal). 
Commercially available antibodies to p-gal make it practical to im­
munolocalize the enzyme [58] . p-gal activity can also be quantified 
biochemically by incubating the live cells or a cell lysate in o-nitro­
phenyl-p-D-galactopyranoside [59]. The reaction product is soluble 
and can be quantified spectrophotometrically at 420 nm. The re­
agents in this assay are not toxic over short periods of time and 
cultivation can be resumed after the assay has been performed. We 
have found this capability to be very useful in screening large num­
bers of cultures of transduced primary keratinocytes. Other reporter 
genes that have been introduced into keratinocytes include CAT, 
luciferase, neuropeptide P, and SV 40 T antigen. 
It should be noted that none of the selectable or reporter genes 
thus far tested seem to have deleterious effects on keratinocyte 
growth potential or differentiation [60,31]' Furthermore, trans­
genic mice expressing p-gal in keratinocytes do not appear to un­
dergo changes or transformations when compared to normal mouse 
keratinocytes [61]. 
Transduction of Epithelial Stem Cells The replicating popu­
lation of cells in epidermis is heterogenous. Included in this popula­
tion are stem cells that are the true progenitor cells and transit 
amplifying cells that replicate a set number of cycles before differ­
entiating [62]. 
In culture, the replicating population of cells is also heterogenous 
[63,64]. It is likely to include stem cells in light of the fact that 
cultured keratinocytes can form a permanent autologous graft [3] 
and that clones of transduced newborn foreskin keratinocytes can be 
expanded routinely to 109 and to 1010 cells before showing signs of 
senescence [31]. However, the difficulty of getting stable transfec­
tion in keratinocytes may be primarily due to unsuccessful targeting 
of the; stem cell population. Future directions in this regard will be 
to,gauge the long-term phenotype of transduced cells and to enrich 
for and target stem cells of epidermal tissue [64] . 
Promoters 
Exogenous: An important aspect of both transient and stable gene 
expression is the choice of promoter to regulate transcription. High 
levels of transcription have been achieved through the use of a 
variety of viral promoters that yield constitutively, high levels of 
gene expression in keratinocytes [36]. However, viral promoters do 
not usually sustain high levels of expression in transduced keratino­
cytes. Examples of down-regulation of viral promoters have been 
observed in keratinocyte lines [37] as well as in normal keratinocytes 
[38]. Transcriptional silencing of an endogenous promoter located 
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Table ID. Examples of Dominant Selectable Markers [77] 
Enzyme Drug for Selection Mechanism. 
Aminoglycoside phosphotransferase (APH) 
Dihydrofolate reductase (DHFR) 
Hygromycin-B-phosphotransferase (HPH) 
Xanthine-guanine phosphoribosyltransferase (XGPRT) 
Adenosine deaminase (ADA) 
Geneticin (G418) 
Methotrexate (Mtx) 
Hygromycin-B 
Mycophenolic acid 
9-/l-o-xylofuronosyl adenine 
APH inactivates G418 (10) 
DHFR resistant to Mtx [78] 
HPH inactivates hygromycin-B [11] 
XGPRT synthesizes GMP from xanthine [79] 
ADA inactivates Xyl-A 
downstream of a viral promoter in an expression cassette ha� also 
been seen [65]. ' 
When genetically transformed cells are transplanted back to the 
host, expression of genes regulated by exogenous promoters is short 
lived. A detailed analysis of this phenomenon was carried out by 
Palmer et al [66] with rat fibroblasts transduced with the genes for 
neo' and human adenosine deaminase (hADA). The cells were 
transplanted into isogeneic rats as dermal equivalents. hADA activ­
ity was present in the graft at 2 weeks post-transplantation, but by 1 
month was undetectable. Semiquantitative PCR analysis of DNA 
extracted 8.5 months post-transplantation showed that hADA 
DNA had indeed persisted at undiminished levels. Furthermore, 
vector positive fibroblasts cultured from the tissue at 8.5 months 
failed to express the neo' phenotype. These studies, and others 
[38,60], indicate that even if transduced cells survive, virally en­
coded genes are gradually inactivated. 
Certain foreign promoters may permit modulated expression in a 
keratinocyte graft. For example, inclusion of a steroid hormone 
receptor element in the inserted construct may permit deliberate 
up-regulation of the encoded gene by topical application of a suit­
able steroid [67]. 
Erulogenous: The issue of inadequate long-term expression using 
viral promoters may be solved by the use of endogenous cellular 
promoters. Although it is possible to utilize an endogenous pro­
moter such as the fJ-actin, it may be desirable to use tissue-specific 
promoters to restrict expression to keratinocytes and to avoid pro­
miscuous expression in non-target tissue. The use of a particular 
endogenous promoter to drive foreign gene expression appears to 
have no deleterious effect on expression of the endogenous gene 
from which the promoter was derived [68]. 
Candidate tissue-specific promoters of genes expressed primarily, 
or exclusively, in keratinocytes include promoter regions for keratin 
genes, involucrin, filaggrin, and loricrin. Keratin promoters have 
successfully been used to direct tissue- and strata-specific expression 
of foreign genes in transgenic mice [68,69]. In a recent report, 
transgenic mouse lines were generated using the involucrin pro­
moter linked to the fJ-gal reporter gene. In the resulting lines, fJ-gal 
was expressed in the suprabasal compartment of epithelial cells indi­
eating that the promoter is expressed not onII in a strata-specific 
fashion but also in a tissue-speCific expression L70]. 
It has been suggested that directing gene expression to basal cells 
may enhance systemic uptake of a secreted gene product [71]. Ex­
pression in the basal layers can be achieved through the use of a basal 
cell-specific promoter such as the keratin 14 promoter. Alterna­
tively, the use of promoters such as that of keratin 1, keratin 10, or 
involucrin would target suprabasal, more transcriptionally active 
keratinocyte cell layers that might assure high levels of expression 
exclusively in stratified epithelia. Finally, it may be useful to use 
promoters such as that of the keratin 6 that are active during hyper­
proliferation. 
IN VIVO KERATINOCYTE GENE TRANSFER 
Techniques to introduce genes directly into animals (in vivo) with­
out having to resort to manipulations in culture have been explored. 
In vivo gene transfer in cells other than keratinocytes has been 
achieved using calcium phosphate precipitation [72], DNA encap­
sulated within liposomes [73], or by direct injection of DNA and 
RNA [74]. DNA has also been introduced in mice intrahepatically 
and intradermally using microprojectiles to shoot the DNA directly 
into the animal [75]. 
To date, the only data of in vivo gene transfer to keratinocytes was 
reported by Dennis Roop.· Using an adenovirus vector containing 
the bacterialfJ-gal gene at a titer of5 X 1010 colony-forming units/ 
ml murine keratinocytes were infected in situ. In this as well as all 
the other in vivo experiments, high initial levels of expression are 
observed but expression is short lived and usually disappears within 
1 month. Because these types of protocols are used directly on the 
animal, drug selection and characterization of individual clones are 
not possible. 
Future Directions Transfer and expression of foreign DNA has 
been accomplished in keratinocytes using a variety of techniques. 
Nevertheless, none of these techniques have given long term, stable 
expression of genes introduced into primary keratinocytes. Future 
developments, particularly with respect to expression vectors, selec­
tion, stem cell identification, and stable targeted expression via en­
dogenous promoters must all be addressed. Information on the con­
sequences of over-expression of a foreign gene in keratinocytes is an 
area of great importance that also must continue to be explored. 
The introduction of genes into keratinocytes has conceivable ap­
plications that are beyond the scope of this review. The potential of 
creating genetically modified keratinocytes for therapy is one possi­
bility discussed elsewhere [76]. Introducing foreign DNA into ker­
atinocytes both in vivo and in vitro holds great promise not only for 
clinical applications but also for basic research. For example, the 
question of secretory capacity by kera�ocytes and epidermal grafts 
can be investigated by introducing genes into these cells and assay­
ing for product. 
This is an exciting field that undoubtedly will continue to be an 
area of much research. 
Note Added in Proof Two germane articles have recently appeared 
on the subject of gene transfer in keratinocytes: 1) Setoguchi Y, et al: 
Recombinant adenoviral vectors have been used to transfer genes 
into primary cultured keratinocytes and injected directly into skin.] 
Invest Dermatol 102:415-421, 1994; and 2) Staedel C, etal: A simple 
and highly efficient transfection technique for primary cultured 
keratinocytes using a lipopolyamine: DNA complex has been de­
veloped.] Invest Dermatoll02:768-772, 1994. 
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